These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 16287440)

  • 1. ODAM is a predictor for biomedical recurrence and inhibits the migration and invasion of prostate cancer.
    Luo Y; Wu JY; Hou GL; Lu MH; Shi Z; Di JM
    Am J Transl Res; 2016; 8(2):670-9. PubMed ID: 27158359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent Prostate Cancer: Is It Clinically Meaningful?
    Childs DS; Orme JJ; Ravi P
    J Clin Oncol; 2024 Apr; 42(10):1095-1097. PubMed ID: 38261976
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of surgical trauma and intraoperative blood loss on tumour progression.
    Jin X; Han H; Liang Q
    Front Oncol; 2024; 14():1412367. PubMed ID: 38912060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer volume estimations based on transrectal ultrasonography-guided biopsy in order to predict clinically significant prostate cancer.
    Konyalioglu E; Tarhan H; Cakmak O; Pala EE; Zorlu F
    Int Braz J Urol; 2015; 41(3):442-8. PubMed ID: 26200537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
    Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
    BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy.
    Antunes AA; Srougi M; Dall'Oglio MF; Crippa A; Campagnari JC; Leite KR
    BJU Int; 2005 Dec; 96(9):1258-63. PubMed ID: 16287441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
    Swindle P; Eastham JA; Ohori M; Kattan MW; Wheeler T; Maru N; Slawin K; Scardino PT
    J Urol; 2005 Sep; 174(3):903-7. PubMed ID: 16093984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence.
    Jones TD; Koch MO; Lin H; Cheng L
    BJU Int; 2005 Dec; 96(9):1253-7. PubMed ID: 16287440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens.
    Epstein JI; Amin M; Boccon-Gibod L; Egevad L; Humphrey PA; Mikuz G; Newling D; Nilsson S; Sakr W; Srigley JR; Wheeler TM; Montironi R
    Scand J Urol Nephrol Suppl; 2005 May; (216):34-63. PubMed ID: 16019758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies.
    Montironi R; Mazzuccheli R; Scarpelli M; Lopez-Beltran A; Fellegara G; Algaba F
    BJU Int; 2005 Jun; 95(8):1146-52. PubMed ID: 15877724
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.